VC
COLL icon

Vivo Capital’s Collegium Pharmaceutical COLL Stock Holding History

Vivo Capital’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-447,173
Closed -$7.3M – 55
2020
Q1 		$7.3M Buy
+447,173
New +$9.23M 0.66% 35

Other funds holding COLL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vivo Capital's COLL Position: Q2 2020 in Review

Vivo Capital sold out of Collegium Pharmaceutical (COLL) in Q2 2020, closing a stake of 447,173 shares — an estimated $7.3M sold.

Vivo Capital first reported a position in COLL in Q1 2020 and held it in 1 quarter. The position peaked at $7.3M in Q1 2020. 150 funds tracked by Wall St. Rank hold COLL as of Q2 2020.

  • Vivo Capital reported no remaining Collegium Pharmaceutical position as of Q2 2020 after selling out during the quarter.
  • Vivo Capital sold 447,173 Collegium Pharmaceutical shares in Q2 2020, an estimated $7.3M.
  • Vivo Capital first reported a position in Collegium Pharmaceutical in Q1 2020 and held it in 1 quarter.
  • Vivo Capital's Collegium Pharmaceutical position peaked at $7.3M in Q1 2020.
  • 150 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2020.

Based on Vivo Capital's 13F filing for Q2 2020, filed 14 Aug 2020.